Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2025 (Event Date)
Reporting Period: The filing primarily addresses corporate governance changes effective November 12, 2025, and incorporates by reference a press release dated November 14, 2025, regarding Third Quarter 2025 financial results.
Key Financial Metrics and Debt Status
The filing text does not provide specific revenue, profit, or cash flow figures for the Third Quarter 2025, as these are contained in the attached press release (Exhibit 99.1) which is not included in the source text. However, the filing details significant historical debt activity and related party transactions:
- Bridge Loan (HCWG LLC): A non-interest-bearing loan with a 50% Original Issue Discount (OID). As of December 31, 2024, the principal outstanding was $9,802,697. On June 14, 2024, the total outstanding principal and interest of $11,748,464 was converted into 979,039 shares of common stock at $12.00 per share.
- Loss on Extinguishment: The conversion of the Bridge Loan resulted in a recorded loss of $2,069,923 due to the difference between the carrying value ($9,678,541) and the fair value of shares issued ($11,748,464).
- Line of Credit: A $10.0 million facility with HCWG LLC entered into on October 11, 2024, bearing 10.0% interest (increasing to 14% if extended). Maturity is October 12, 2027.
- Warrant Exercise: In April 2025, 164,500 shares were issued to HCWG following a cashless exercise of a warrant associated with the Line of Credit.
- Related Party Settlement: A $4,000,000 payment is due to Orient EuroPharma Co., Ltd. (OEP) within ten days of the Company's IPO to terminate a prior collaboration agreement.
Material Changes and Governance Events
Board of Directors Changes:
- Resignation: Ishwar K. Puri tendered his resignation on November 12, 2025, following an objection from the University of Southern California regarding his appointment.
- Re-election: Dr. Ming-Fu Chiang was elected to the Board effective November 12, 2025, serving until the 2026 annual meeting. Dr. Chiang had previously resigned in August 2025.
Related Party Transactions:
- Dr. Chiang holds a 18.75% ownership interest in HCWG LLC, the lender for the Bridge Loan and Line of Credit.
- Dr. Chiang was granted 50,000 restricted stock units (RSUs) in February 2025, which vested 100% on October 25, 2025.
- Orient EuroPharma Co., Ltd. (OEP), partially owned by Dr. Chiang, is owed $4,000,000 upon the Company's IPO.
Guidance, Outlook, and Risks
Outlook: The filing references a press release for Q3 2025 results but does not contain specific forward-looking guidance or management commentary within the text provided.
Risks and Contingencies:
- Liquidity and Debt: The Company relies on related-party financing (HCWG LLC) for liquidity. The Bridge Loan has been extinguished, but the Line of Credit remains active.
- Related Party Conflicts: Significant financial relationships exist between the Company and entities owned by Dr. Chiang (HCWG LLC and OEP), including debt, equity, and settlement obligations.
- Regulatory Compliance: The filing explicitly states that the financial information in the press release is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific Q3 2025 revenue, net income, and cash flow figures in the attached Press Release (Exhibit 99.1), as they are not present in this 8-K text.
- Confirm the status of the $4,000,000 settlement payment to OEP and the timeline for the Company's Initial Public Offering (IPO).
- Review the terms of the $10.0 million Line of Credit with HCWG LLC, specifically the interest rate conditions and maturity date.
- Assess the impact of the $2,069,923 loss on extinguishment of the Bridge Loan on the Company's historical financial statements.
- Monitor the composition of the Board of Directors following the re-election of Dr. Ming-Fu Chiang and the resignation of Mr. Puri.